Strong partners ensure efficient market access
Who is Novaliq partnering with?
- Novaliq has an European Partnership Agreement with Ursapharm, one of the leading EU ophthalmic players. In October 2015, NovaTears® entered the EU market under Ursapharm’s brand name EvoTears®. Since then, EvoTears® has been successfully launched in 16 EU countries.
- Novaliq has a strategic Licencing Partnership Agreement with AFT Pharmaceuticals Ltd (AFT), a New Zealand-based pharmaceutical company listed in ASX and NZX, for the commercialization of NovaTears® in Australia and New Zealand.
- In April 2019, Novaliq has founded Betaliq Inc., Tampa USA in collaboration with BLP Management Group, LLC. Betaliq develops ophthalmic beta-blockers using Novaliq’s proprietary EyeSol® water-free technology.
- Novaliq is working with leading academic and industry partners including CROs, CMOs offering product development expertise and execution capabilities through pre-clinical IND, clinical development and regulatory in USA, Europe, China and Japan.
Do you want to partner with us?